This post was originally published on this site
https://i-invdn-com.investing.com/trkd-images/LYNXNPEJ9204U_L.jpg
The agreements effectively resolve all pending claims filed against the company for failing to warn patients about the risk of contracting chronic kidney disease and related issues, except for one in Louisiana, AstraZeneca said – the trial for which is scheduled in April next year.
The company added that it has taken a provision for the settlement payment.
